You may not log in without verifying your email address.
Please check your email (including your spam email) for the Welcome message that was sent.
Cdc7/Cdk9 Inhibitor is a cell-permeable pyrrolopyridinone compound that acts as a potent, reversible, and ATP-competitive inhibitor of Cdc7 and Cdk9 (IC50 = 10 and 34 nM, respectively). Reported to have good selectivity over a panel of 31 other kinases, including GSK-3β, Cdk2, Cdk1, Cdk5, MK-2, Plk1, and Chk2 (IC50 = 0.22, 0.24, 0.25, 0.46, 0.47, 0.98, and 1.1 μM, respectively). It has been shown that cellular treatment of PHA76749 with Cdc7/Cdk9 Inhibitor results in a prevention of the activation of DNA replication origins without the inhibition of replication fork progression. Cdc7/Cdk9 Inhibitor is also reported to inhibit the proliferation of 61 cell lines in vitro (IC50 ≤ 10μM) and exhibit antitumor activity. Cdc7/Cdk9 Inhibitor is an inhibitor of MAPKAPK-2.
1. Montagnoli, A., et al. 2008. Nat Chem Biol. 4: 357-365. PMID: 18469809
2. Vanotti, E., et al. 2008. J. Med. Chem. 51: 487-501. PMID: 18201066
3. Anderson, D.R., et al. 2007. J. Med. Chem. 50, 2647-2654. PMID: 17480064
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.